Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 268,432 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the sale, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Checkpoint Therapeutics Price Performance

CKPT stock opened at $3.75 on Friday. The stock has a market capitalization of $183.12 million, a P/E ratio of -2.04 and a beta of 1.34. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The business has a 50-day moving average of $3.57 and a 200-day moving average of $2.70.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Equities analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CKPT. Virtu Financial LLC bought a new position in shares of Checkpoint Therapeutics in the 3rd quarter valued at about $30,000. XTX Topco Ltd bought a new position in Checkpoint Therapeutics in the second quarter valued at approximately $34,000. Gladstone Institutional Advisory LLC grew its stake in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 20,500 shares in the last quarter. Magnus Financial Group LLC raised its stake in shares of Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Choreo LLC boosted its holdings in shares of Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after buying an additional 7,080 shares during the last quarter. 22.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CKPT has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital increased their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.